A Real-World Evaluation of Brain Imaging in Patients with Advanced Non-Small Cell Lung Cancer: Insights from a German Claims Data Analysis
Oncology
BIOGRAPHY
Marc Pignot
Dr. Marc Pignot joined ZEG Berlin to lead the implementation and development of Real-World Evidence & Safety Data Analytics.
Marc has more than 20 years of experience in the pharmaceutical and CRO business. As Chief Strategy Officer, he is establishing a strong secondary data stream to complement and combine with ZEG Berlin’s long-established primary data business. Real-World Evidence and services bridge the growing need for leading-edge secondary data collection with ZEG Berlin’s classical studies for post-authorization, safety, and effectiveness.
Marc Pignot served as Director of Real-World Evidence, and global consulting at Kantar Health, and as a Director at Kendle, now Syneos Health, a global CRO. He was responsible for conducting global clinical trials and Late Phase programs in the main therapeutic areas.
He also worked on Diagnostic Imaging and Medical Device Studies at Amersham Health and GE Healthcare. Before moving to clinical research, Marc worked with Aventis Pharmaceutical’s global research center focusing on functional genomics and proteomics.
Marc Pignot holds a PhD in Bio-Organic Chemistry from the Max Planck Institute of Molecular Physiology and completed postdoctoral training in nucleic acid chemistry at the University of Frankfurt/Scripps Research Institute (La Jolla).
PUBLICATIONS
2025
Epidemiology and burden of mild/moderate versus high myopia in Germany: A claims data analysis.
Dermatology
Real-world psoriasis treatment patterns and disease burden in Germany, with a focus on biologics and apremilast: data from a German statutory health insurance database
Dermatology
2024
[Clinical courses and costs for hospitalizations of potentially immunocompromised COVID-19 patients in Germany]
Other
The Impact of Systemic Lupus Erythematosus Flares on Clinical and Economic Outcomes: The CHAMOMILE Claims Database Study in Germany
Other
Unveiling the untreated: development of a database algorithm to identify potential Fabry disease patients in Germany
Other
2023
Comorbidities, healthcare resource utilization & treatment pattern among patients with prurigo nodularis, compared to a benchmark in Germany: A real-world evidence claims data study
Dermatology
2022
Clinical Characteristics, Health Care Resource Utilization, and Costs Associated With Flares in Patients With Systemic Lupus Erythematosus in Germany
Other
Prevalence of lupus nephritis among patients with systemic lupus erythematosus in Germany
Other
2020
Evaluation of Treatment Patterns of Fabry Disease Utilizing Medical Claims Analyses of a German Sickness Fund Database
Other
Real-World Cost Difference in Patients With Psoriasis Initiating Apremilast vs. Secukinumab After Conventional Systemic Therapy Using German Sickness Fund Data
Dermatology
Real-World Effectiveness of Osteoporosis Treatments in Germany
Other
Using Data from a Sickness Fund Claims Database to Assess the Treatment Patterns and Healthcare Resource Utilization among Patients with Metastatic Renal Cell Carcinoma in Germany
Oncology
2019
Cardiorenal disease is the most common first CV manifestation in type 2 diabetes and associated with increased mortality: a large multinational observational study
Diabetes
Cardiorenal disease is the most common first CV manifestation in type 2 diabetes and associated with increased mortality: a large multinational observational study
Diabetes